Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (1392)	2/17/2000 3:27:00 PM
From: Torben Noerup Nielsen	Respond to of 4974

All, Any idea of who's supplying all the shares on the sell side of both GLIA and NBIX? I may be getting paranoid, but it seems there's a conscious effort being made to restrain both of them. I've watched NBIX be walked down a bit only to rise up again. But it's nowhere near it's highs for the day. At this rate, I can't afford the Ferrari from todays earnings; I'll just have to settle for yet another S500.... Thanks, Torben

To: Torben Noerup Nielsen who wrote (1392)	2/17/2000 3:30:00 PM
From: Mike McFarland	Respond to of 4974

Well, maybe we will just have to see what Harry has to say about Glia and it's valuation in the months ahead <Prudential report... they're not valuing the biotech pipeline>. Well good for us, should not be whining that it can be had for $22. The marketcap certainly looks awfully low when compared to the hot spots in biotech right now. Check that, the marketcap looks awfully low compared to everything. I should say that Neuro has already been useful --and if Dr. Tracy is lurking...the February issue was helpful and an interesting read for this insomniac.